title: [Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of Compound Xuanju Capsule (CXC) in the treatment of chronic prostatitis with erectile dysfunction (ED).
  
  
  METHODS
  We obtained NIH-CPSI and IIEF-5 scores from 132 chronic prostatitis patients with ED and divided the patients into a control (n = 70) and a treatment group (n = 62), the former treated with oral levofloxacin 0.2 g bid for 4-6 weeks and oral Terazosin at 2 mg qd for 2 months, and the latter with oral CXC once 2 capsules tid for 2 months in addition to the above.
  
  
  RESULTS
  None of the patients had serious medication-related adverse reactions. After treatment, the control group showed significantly decreased NIH-CPSI scores and slightly increased IIEF-5 scores as compared with the baseline (16.5 +/- 5.9 vs 25.1 +/- 5.5, P < 0.05 and 13.1 +/- 5.2 vs 11.3 +/- 4.5, P > 0.05), while the treatment group exhibited significant improvement in both NIH-CPSI (13.4 +/- 5.7 vs 25.5 +/- 5.3, P < 0.05) and IIEF-5 scores (17.5 +/- 6.5 vs 10.8 +/- 3.8, P < 0.05). The total effectiveness rate for ED was significantly higher in the treatment than in the control group (74.2% vs 20%, P < 0.05).
  
  
  CONCLUSIONS
  Compound Xuanju Capsule can significantly alleviate both the symptoms of chronic prostatitis and ED in the treatment of chronic prostatitis patients with ED.
authors.affiliation: Department of Urology, General Hospital of Chengdu Military Region, Chengdu 610083, China. wangliangcd@sina.com
authors.forename: Liang
authors.initials: L
authors.lastname: Wang
authors.forename: Ping
authors.initials: P
authors.lastname: Liang
authors.forename: Wei
authors.initials: W
authors.lastname: Yang
authors.forename: Peng
authors.initials: P
authors.lastname: Zhou
authors.forename: Xiao-Ke
authors.initials: XK
authors.lastname: Huang
authors.forename: Ji-Wen
authors.initials: JW
authors.lastname: Liu
authors.forename: Wen-Feng
authors.initials: WF
authors.lastname: Chao
authors.forename: Hang
authors.initials: H
authors.lastname: Yang
authors.forename: Qing-Tang
authors.initials: QT
authors.lastname: Wang
mesh_terms: D000328:Adult; D002214:Capsules; D002908:Chronic Disease; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use; D008517:Phytotherapy; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011472:Prostatitis / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D064704:Levofloxacin; C041226:Terazosin; D015242:Ofloxacin; D011224:Prazosin